new license agreement with Myriad
November 14, 2018
We have entered into a new license agreement with Myriad to comercialize Endopredict in Argentina. EndoPredict is a 2nd generation breast cancer recurrence test for highly accurate assessment of 10-year risk of distant recurrence. At Varifarma we are committed to improving the future for patients with cancer.
